SEC Filing Summary: Predictive Oncology Inc. (POAI), Form 10-Q
Entity note: The supplied filing is for Predictive Oncology Inc., not Axe Compute Inc. It covers the quarter and nine months ended September 30, 2021; the financial statements are unaudited.
Business context
Predictive Oncology operates in precision medicine and contract research through Helomics, protein-solubility services through Soluble, and medical-fluid-disposal products through Skyline. Management said it intends to focus resources on Helomics and applying AI to precision medicine and drug discovery.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $313,663 | $480,757 | $944,187 | $958,484 |
| Gross profit | $203,498 | $305,551 | $593,387 | $605,360 |
| Gross margin | Approximately 65% | Approximately 64% | Approximately 63% | Approximately 63% |
| Net loss | $5,438,017 | $6,307,726 | $11,900,662 | $14,414,421 |
| Loss per common share | $0.08 | $0.46 | $0.23 | $1.51 |
- For the nine months, operating expenses included $7.41 million in general and administrative expense, $1.79 million in operations expense, and a $2.81 million goodwill impairment charge.
- Cash used in operating activities was $8.46 million for the nine months, versus $9.95 million in the comparable 2020 period. Investing activities used $820,233; financing activities provided $50.38 million.
- At September 30, cash and cash equivalents were $41.77 million, current assets were $43.04 million, current liabilities were $2.99 million, and stockholders’ equity was $47.78 million. The company reported no outstanding debt; lease liabilities remained.
- Cash increased from $678,332 at December 31, 2020, largely reflecting equity financing and warrant exercises. The company raised $50.52 million net from common-stock issuance and received $4.51 million from warrant exercises during the nine months.
Material changes versus comparable periods
- Q3 revenue fell $167,094 year over year; nine-month revenue was down $14,297. Skyline remained the main revenue source, and STREAMWAY unit sales declined to 3 for Q3 and 10 for the nine-month period, from 15 and 21, respectively.
- Net loss improved year over year, partly because other expense and financing costs were substantially lower after the company repaid its notes in March 2021. In Q3 2020, other expense was $2.15 million, compared with $7,413 in Q3 2021.
- Helomics goodwill was fully impaired in Q3 2021, with a $2.81 million charge; the balance was zero at quarter-end. This followed impairment charges in 2019 and 2020.
- Common shares outstanding rose to 65.46 million at September 30 from 19.80 million at December 31, 2020, primarily reflecting equity offerings, warrant exercises, and other share issuances.
Outlook, risks, and unusual items
- Management stated that cash on hand was expected to support its operating plan for the next twelve months and beyond. It also disclosed continuing operating losses and negative operating cash flow, and said it may seek additional debt, equity, or other financing.
- An equity line had $9.20 million of stated capacity remaining at September 30, subject to market and other conditions; further use would be dilutive. The company also cited an active shelf registration statement, subject to availability and limitations.
- The company identified COVID-19-related supplier disruption, delayed production, reduced operating efficiency, limits on hospital sales visits, slower collections, and supplier deposit demands as continuing risks.
- The filing describes substantial potential dilution: 31.73 million warrants were outstanding at September 30, alongside 1.01 million stock options and 516,666 restricted stock units.
- Other key risks include ongoing losses, the possibility of further impairment, dependence on future revenue growth and financing, competition, regulatory requirements, intellectual-property risks, and retaining qualified personnel. No legal proceedings were reported. Management said the previously identified internal-control material weakness was remediated as of June 30, 2021 and disclosure controls were effective at September 30.
Important facts for investors to verify
- Confirm the issuer identity: this filing is Predictive Oncology Inc. (POAI), not Axe Compute Inc.
- Assess whether Helomics can generate meaningful revenue from its AI/CRO strategy; Helomics reported just $11,314 of revenue for the nine months.
- Review the assumptions behind the Helomics goodwill impairment and whether further impairments may be warranted.
- Reconcile cash use and financing needs against management’s stated runway, and check conditions for accessing the remaining equity-line and shelf capacity.
- Evaluate the potential dilution from outstanding warrants, options, restricted stock units, and future equity financing.